MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

FDA Approves Adaptimmune's Groundbreaking Gene Therapy for Rare Cancer

NextEdge Admin

02 Aug 2024

1 min 6 sec

The U.S. Food and Drug Administration (FDA) has approved Adaptimmune's gene therapy, Tecelra, for treating synovial sarcoma, a rare soft tissue cancer primarily affecting young men. This approval marks the first gene therapy in the U.S. that leverages a patient's own T-cells to combat cancer. Tecelra is intended for patients who have previously undergone chemotherapy. The treatment, delivered as a single intravenous dose, is priced at $727,000. It received accelerated approval from the FDA, which necessitates confirmation of its benefits through a subsequent trial. Synovial sarcoma, typically developing in the extremities, affects approximately 1,000 people annually in the U.S., predominantly adult males in their 30s or younger, according to the FDA.